Unknown

Dataset Information

0

Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study.

ABSTRACT:

SUBMITTER: Durand CM 

PROVIDER: S-EPMC8288461 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study.

Durand Christine M CM   Barnaba Brittany B   Yu Sile S   Brown Diane M DM   Chattergoon Michael A MA   Bair Nichole N   Naqvi Fizza F FF   Sulkowski Mark M   Segev Dorry L DL   Desai Niraj M NM  

Annals of internal medicine 20200908 1

Similar Datasets

Unknown Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
| S-EPMC6108432 | biostudies-literature
Unknown Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.
| S-EPMC10725568 | biostudies-literature
Unknown Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors.
| S-EPMC6663314 | biostudies-literature
Unknown Intermediate-term risk of cardiac allograft vasculopathy following heart transplantation from hepatitis C viremic donors in the era of direct-acting antiviral therapy.
| S-EPMC12651725 | biostudies-literature
Unknown Twelve-month kidney and liver outcomes of kidney transplantation from Hepatitis C Viremic deceased donors to aviremic recipients.
| S-EPMC10922352 | biostudies-literature
Unknown Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis.
| S-EPMC9158331 | biostudies-literature
Unknown The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients.
| S-EPMC5945716 | biostudies-literature
Unknown Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
| S-EPMC5131925 | biostudies-literature
Unknown Trends in Discard of Kidneys from Hepatitis C Viremic Donors in the United States.
| S-EPMC7863640 | biostudies-literature
Unknown Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients.
| S-EPMC8216294 | biostudies-literature